A $30M raise that stands apart
While early-stage biotech AI companies typically attract $5–15M, Astromech’s $30M debut positions it as an outlier. SEC filings confirm the raise, with few details disclosed, but the size suggests heavyweight venture participation.
Betting on biotech + AI convergence
The convergence of biotech and AI has already minted billion-dollar stories — Recursion, Insitro, Isomorphic Labs. Astromech enters that race with a dual advantage: Ben Lamm’s
